Open AccessPituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets
Author(s) -
Terry W. Moody,
Robert T. Jensen
Publication year - 2021
Publication title -
current opinion in endocrinology, diabetes and obesity./current opinion in endocrinology, diabetes and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.199
H-Index - 67
eISSN - 1752-2978
pISSN - 1752-296X
DOI - 10.1097/med.0000000000000617
Subject(s) - vasoactive intestinal peptide , receptor , biology , signal transduction , adenylate kinase , intracellular , cyclase , molecular pharmacology , neuroscience , neuropeptide , microbiology and biotechnology , biochemistry
To discuss recent advances of vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in pharmacology, cell biology, and intracellular signaling in cancer.